A simple algorithm with one flow cytometric MRD measurement identifies more than 40% of children with ALL who can be cured with low-intensity therapy. The ALL-MB 2008 trial results.

Autor: Popov A; National Research and Clinical Center for Pediatric Hematology, Oncology and Immunology, Moscow, Russian Federation. uralcytometry@gmail.com., Henze G; Department of Pediatric Oncology Hematology, Charité - Universitätsmedizin Berlin, Berlin, Germany., Roumiantseva J; National Research and Clinical Center for Pediatric Hematology, Oncology and Immunology, Moscow, Russian Federation., Budanov O; National Research and Clinical Center for Pediatric Hematology, Oncology and Immunology, Moscow, Russian Federation.; Belarussian Research Center for Pediatric Oncology, Hematology and Immunology, Minsk, Belarus., Belevtsev M; Belarussian Research Center for Pediatric Oncology, Hematology and Immunology, Minsk, Belarus., Verzhbitskaya T; Regional Children's Hospital, Ekaterinburg, Russian Federation.; Research Institute of Medical Cell Technologies, Ekaterinburg, Russian Federation., Boyakova E; Moscow City Blood Center named after OK Gavrilov, Moscow, Russian Federation., Movchan L; Belarussian Research Center for Pediatric Oncology, Hematology and Immunology, Minsk, Belarus., Tsaur G; Regional Children's Hospital, Ekaterinburg, Russian Federation.; Research Institute of Medical Cell Technologies, Ekaterinburg, Russian Federation., Fadeeva M; National Research and Clinical Center for Pediatric Hematology, Oncology and Immunology, Moscow, Russian Federation., Lagoyko S; National Research and Clinical Center for Pediatric Hematology, Oncology and Immunology, Moscow, Russian Federation., Zharikova L; National Research and Clinical Center for Pediatric Hematology, Oncology and Immunology, Moscow, Russian Federation., Miakova N; National Research and Clinical Center for Pediatric Hematology, Oncology and Immunology, Moscow, Russian Federation., Litvinov D; National Research and Clinical Center for Pediatric Hematology, Oncology and Immunology, Moscow, Russian Federation., Khlebnikova O; Regional Children's Hospital, Ekaterinburg, Russian Federation., Streneva O; Regional Children's Hospital, Ekaterinburg, Russian Federation.; Research Institute of Medical Cell Technologies, Ekaterinburg, Russian Federation., Stolyarova E; Belarussian Research Center for Pediatric Oncology, Hematology and Immunology, Minsk, Belarus., Ponomareva N; Republican Children's Hospital, Moscow, Russian Federation., Novichkova G; National Research and Clinical Center for Pediatric Hematology, Oncology and Immunology, Moscow, Russian Federation., Fechina L; Regional Children's Hospital, Ekaterinburg, Russian Federation.; Research Institute of Medical Cell Technologies, Ekaterinburg, Russian Federation., Aleinikova O; Belarussian Research Center for Pediatric Oncology, Hematology and Immunology, Minsk, Belarus.; National Research and Clinical Center for Pediatric Hematology, Oncology and Immunology, Moscow, Russian Federation., Karachunskiy A; National Research and Clinical Center for Pediatric Hematology, Oncology and Immunology, Moscow, Russian Federation.
Jazyk: angličtina
Zdroj: Leukemia [Leukemia] 2022 May; Vol. 36 (5), pp. 1382-1385. Date of Electronic Publication: 2022 Mar 23.
DOI: 10.1038/s41375-022-01542-z
Databáze: MEDLINE
Externí odkaz: